Article info

Download PDFPDF
Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review
  1. Correspondence to Christine Schmucker, German Cochrane Centre, Institute of Medical Biometry and Medical Informatics, Department of Medical Biometry and Statistics, University Medical Centre Freiburg, Berliner Allee 29, Freiburg 79110, Germany; schmucker{at}cochrane.de
View Full Text

Citation

Schmucker C, Loke YK, Ehlken C, et al
Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review

Publication history

  • Accepted March 23, 2010
  • First published October 22, 2010.
Online issue publication 
February 17, 2011

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.